Last reviewed · How we verify
Product A
Product A is a marketed pharmaceutical from Galderma R&D, but specific mechanistic details are not provided.
At a glance
| Generic name | Product A |
|---|---|
| Also known as | Adapalene |
| Sponsor | Galderma R&D |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Without additional information about the drug's active ingredient, molecular target, or therapeutic class, a detailed mechanistic explanation cannot be accurately provided. Galderma R&D primarily focuses on dermatology and aesthetic medicine products.
Approved indications
Common side effects
Key clinical trials
- Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma (PHASE2)
- A Phase 1 Study of IM-1021 in Participants With Advanced Cancer (PHASE1)
- Screening and Multiple Intervention on Lung Epidemics (PHASE2)
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure) (NA)
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC (EARLY_PHASE1)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Product A CI brief — competitive landscape report
- Product A updates RSS · CI watch RSS
- Galderma R&D portfolio CI